Back to press releases
  • Group
  • Press release

BNP Paribas CIB renews its partnership with the Institut Pasteur

For the fifth consecutive year, BNP Paribas Corporate & Investment Banking is sponsoring the Institut Pasteur, supporting medical research in 15 countries

BNP Paribas Corporate & Investment Banking (CIB) has renewed its partnership with the Institut Pasteur bringing financial support to scientific teams in 15 countries, in accordance with the medical research sponsoring policy of the BNP Paribas Foundation. Since 2008,
BNP Paribas CIB has pledged more than EUR 2 million in financial support.

Increasingly, the Institut Pasteur research projects are specifically linked to public health problems encountered in each country. The programs sponsored by BNP Paribas CIB include, for example, the development of a combined vaccine against measles and AIDS in France and United Kingdom and research on various diseases such as hepatitis (Japan, Spain, and Russia), malaria (Brazil), dengue fever (Hong-Kong), and E.coli (Canada and Belgium).

In 2012 several major breakthrough discoveries in key medical fields were made by Pasteur scientists. These discoveries were made possible thanks to the Institut Pasteur donors (corporate and individuals). Donations represent nearly 30% of the foundation's budget. BNP Paribas has built very strong links with the Institut Pasteur, sponsoring medical research through its Corporate and Investment Bank and several of its affiliates. To date, BNP Paribas Group is one of the most important partners of Institut Pasteur.

2012 Pasteur scientists major breakthrough discoveries :

- Bacterial diseases: tuberculosis, whooping cough, meningitis, cholera…
The annual report published on April 19th, 2012, demonstrates that researchers from the Institut Pasteur and Inserm, in collaboration with the University of Pisa, took a major step forward, in the scientific quest to develop a more efficient vaccine against tuberculosis.

- Furthermore the cooperation between the Institut Pasteur, the CNRS, and the University of Tsukuba Faculty of Medicine (Japan) has proven for the first time that activating a specific gene in Staphylococcus aureus enables it to resist methicillin antibiotic.

- Genetic diseases: autism, Sanfilipo disease…
An international partnership including the Institut Pasteur has made new genetic findings which confirm the neurobiological origins of autism disorders relatively unknown until now.

- Neurodegenerative diseases: Alzheimer, Parkinson, Huntington's chorea…
Newly discovered characteristics of neo-neurons to assimilate complex information could open up new opportunities in the treatment of some neurodegenerative diseases.

- Cancers.
Scientists from the Institut Pasteur and the CNRS have recently identified a protein that can cause a dysfunction which leads to the development of several types of cancer. This work reveals a potential therapeutic target for the treatment of certain tumors as announced on February 24th, 2012. Other researches found how to reinforce effects of the BCG vaccine, which has been the standard treatment for bladder cancer.

- Parasitic diseases: malaria, Chagas disease, leshmaniasis…
On the 27th of September, an official publication announced that the Institut Pasteur and the CNRS, in collaboration with Imperial College London, had synthesized two molecules able to quickly and irreversibly stop the growth of themalarial parasite.

- Stem cells and regenerative medicine.
In 2012, the capacity of stem cells to adopt a dormant state when their environment becomes hostile has been shown by five teams of scientists, including one at the Institut Pasteur. This discovery could lead to new therapeutic avenues for treating numerous diseases.

- A new research center.
Emergent or re-emergent diseases (SARS, H1N1 flu, Chikungunya…) are increasing worldwide. In order to study them adequately, the Institut Pasteur started in 2008 the construction of the new “Center for research on emerging diseases”, finally inaugurated in November 2012.

About BNP Paribas Corporate and Investment Banking
BNP Paribas Corporate and Investment Banking (CIB) is a leading provider of solutions to a wide range of clients including corporates, sovereigns, financial institutions and investors worldwide. Approximately 19,000 professionals in 45 countries provide clients with personalized services for managing their risks and assets, financing and expanding their business and servicing their operational needs.
BNP Paribas CIB excels in:
Corporate Banking - wherPress contact:Press contact:e it has leading franchises in Transaction Banking (trade finance, cash management) and in Specialized Financing (energy & commodities, transportation, export, project, leveraged, media telecom, corporate acquisition finance and real estate)
Derivatives - where it is one of the leading global players in interest rates, credit, foreign exchange, commodity and equity derivatives.
Advisory and Capital Markets - where it is a top European house in ECM and a global leader in DCM (bond, convertibles and equity issuance)
BNP Paribas has been named “Bank of the Year 2012” by the International Financing Review.

About Institut Pasteur
Louis Pasteur created the Institut Pasteur in 1887 as a private non-profit foundation that rapidly became worldrenowned for its biomedical research. The main aim of the Institut Pasteur is understanding and preventing diseases throughout the world through excellent scientific and public health research, teaching and other activities. Together with its major contribution to a deeper understanding of fundamental aspects of life, the Institut Pasteur continues to devote a large part of its efforts to infectious diseases, inherited disorders, neurodegenerative diseases and certain cancers. Close to 2,600 people work on its main campus in Paris, which is at the heart of an international network of 32 research institutes on 5 continents. Over the years, 10 Institut Pasteur researchers have received the Nobel Prize.